deep dives into generic leaders—such as Teva, Sandoz, and Viatris—and more. Download the report to learn how to leverage these top companies’ growth plans for your investing strategy.

The story of the deal began in July 2015, when Teva announced the acquisition of Allergan’s generic business for a total consideration ... credit investors’ commitment to Teva’s long-term strategy. To ...